The efficacy of PARP inhibitor against gastrointestinal cancer
| Project/Area Number |
25460930
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Kubota Eiji 名古屋市立大学, 医学(系)研究科(研究院), 講師 (30405188)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATAOKA HIROMI 名古屋市立大学, 医学(系)研究科(研究院), 准教授 (40381785)
MIURA YUTAKA 名古屋市立大学, 医学(系)研究科(研究院), 准教授 (90285198)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 消化器癌 / ATM / PARP阻害剤 / 胃癌 / 大腸癌 |
|---|
| Outline of Final Research Achievements |
In this study, we revealed the efficacy of PARP inhibitor is significantly associated with the expression level of Ataxia telangiectasia mutated (ATM) protein. Additionally, we showed that ATM inhibitor sensitized the effect of PARP inhibitor in gastric cancer cell lines with p53 disruption. Our study demonstrated the utility of ATM as a biomarker of PARP inhibitor for gastric cancer patients. Moreover, our date revealed the possibility that PARP inhibitor in combination with ATM inhibitor is effective for p53-mutant gastric cancer.
|
Report
(4 results)
Research Products
(5 results)
